Hepatobiliary Tumors Tissue Samples Acquisition

UnknownOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

October 11, 2020

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Hepatocellular CarcinomaCholangiocarcinomaGallbladder CancerBiliary Tract CancerLiver CancerPrecancerous ConditionBenign Hepatobiliary DiseaseHealthy, no Evidence of Disease
Interventions
OTHER

Gene expression analysis

Gene expression analysis

OTHER

Genomic analysis

Genomic analysis

OTHER

Protein expression analysis

Protein expression analysis

OTHER

Proteomic profiling

Proteomic profiling

OTHER

Polymerase chain reaction

Polymerase chain reaction

OTHER

Mass spectrometry

Mass spectrometry

OTHER

Immunohistochemistry

Immunohistochemistry

OTHER

Metabolomics profiling

Metabolomics profiling

OTHER

Methylation and epigenetic analysis

Methylation and epigenetic analysis

OTHER

Liquid biopsy analysis

Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis

OTHER

Laboratory biomarker analysis

Laboratory biomarker analysis (such as AFP, CA19-9, CEA)

Trial Locations (1)

100730

RECRUITING

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

OrigiMed

INDUSTRY

collaborator

GeneCast Biotechnology Co., Ltd.

INDUSTRY

collaborator

YuceBio Technology Co., Ltd.

UNKNOWN

collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition | Biotech Hunter | Biotech Hunter